Thesis (Ph.D)--Virginia Commonwealth University, 2009. / Prepared for: Dept. of Biochemistry. Title from resource description page. Includes bibliographical references.

Tumor metastasis is a fundamental property of malignant cancer cells and the major cause of death in cancer patients. Recent studies indicate that tumor cell invasion and metastasis may be initiated by the formation of the actin-rich cell protrusions with ECM degradation activity, invadopodia. However, despite extensive research on the biology of invadopodia, very little is known about their specific inducers during tumor progression. Autotaxin (ATX) is a secreted lysophospholipase whose expression levels within tumors correlates strongly with their aggressiveness and invasiveness. ATX produces lyosophosphatidic acid (LPA), a phospholipid with known tumor promoting functions that acts through the G-protein coupled receptors, LPA[subscript 1-6] . Recently, overexpression of ATX and LPA receptors (LPA[subscript 1-3]) has been linked to increased tumor invasion and metastasis in vivo , however, the role of other LPA receptors (LPA[subscript 4-6]) as well as the exact mechanisms by which ATX induces tumor metastasis remain poorly characterized. In order to determine the involvement of ATX and LPA in invadopodia production, we used the fibrosarcoma HT-1080 cells stably transfected with ATX or shRNA targeting ATX in fluorescent matrix degradation assays. Our results demonstrate that ATX is implicated in the production of invadopodia resulting in an increase in both their formation and function. Using LPC or LPA, the substrate and product of ATX, we further show that invadopodia production is dependent on the production of LPA from LPC. Among the LPA receptors, LPA 4 has the highest expression in HT1080 cells. Using LPA[subscript 4] shRNA as well as agonists and inhibitors of the cAMP pathway, we provide evidence that LPA[subscript 4] signaling through the cAMP-EPAC-Rap1 axis, regulates invadopodia formation downstream of ATX. Furthermore, inhibition of Rac1, a known effector of Rap1 and invadopodia formation, abolished EPAC-induced invadopodia production, suggesting downstream participation of Rac1. Finally, results using LPA[subscript 4] shRNA support the requirement of this receptor for in vitro cell invasion and in vivo metastasis formation. Our results suggest that ATX through LPA[subscript 4] is a strong inducer of invadopodia formation that correlates with the ability of the cells to invade and metastasize. This study also revealed an unexpected signaling pathway for cell invasion involving LPA[subscript 4]-driven cAMP production and subsequent activation of the EPAC-Rap1-Rac1 axis.

Thesis (Ph. D.)--University of Virginia, 2008. / Includes bibliographical references. Also available in electronic form as viewed 2/16/2009.

京都大学 / 0048 / 新制・課程博士 / 博士(農学) / 甲第21841号 / 農博第2354号 / 新制||農||1069(附属図書館) / 学位論文||H31||N5213(農学部図書室) / 京都大学大学院農学研究科応用生命科学専攻 / (主査)教授 栗原 達夫, 教授 植田 充美, 教授 小川 順 / 学位規則第4条第1項該当 / Doctor of Agricultural Science / Kyoto University / DGAM

Lysophosphatidic acid (LPA) belongs to a class of extracellular lipid signaling molecules. In the vasculature, LPA may regulate platelet activation and modulate endothelial and smooth muscle cell function. LPA has therefore been proposed as a mediator of cardiovascular disease. The bulk of circulating LPA is produced from plasma lysophosphatidylcholine (LPC) by autotaxin (ATX), a secreted lysophospholipase D (lysoPLD). Early studies suggest that some of the production of circulating LPA is platelet-dependent. ATX possesses an N-terminal somatomedin B-like domain suggesting the hypothesis that ATX interacts with platelet integrins which may localize ATX to substrate in the membrane and/or alter the catalytic activity of ATX. Using static adhesion and soluble binding assays we found that ATX does indeed bind to platelets and cultured mammalian cells in an integrin-dependent manner which is blocked by integrin function-blocking peptides and antibodies. This binding increases both the activity of ATX and localization of its product, LPA, to the platelet/cell membrane. LPA is generally stimulatory to human platelets although platelets from a small population of donors are refractory to LPA stimulation. Likewise LPA is inhibitory to murine platelets. We previously found that LPA receptor pan-antagonists reduce agonist-induced platelet activation, and partial stimulation of LPA5 specifically increases platelet activation in humans. Since both LPA5 and LPA4 are present at significant levels in human platelets, we hypothesized that LPA4 is responsible for an inhibitory pathway and LPA5 is responsible for an inhibitory pathway. We used mice deficient in LPA4 to test this model. Isolated platelet function tests revealed no major difference between lpa4-/- mice compared with WT mice although lpa4-/- mice were more prone to FeCl3-induced thrombosis. Paradoxically, chimeric mice reconstituted with lpa4-/- deficient bone marrow derived cells were protected from thrombosis. These discrepancies may be explained by involvement of endothelial cells and the relative scarcity of LPA receptors in murine platelets compared with human platelets. Taken together, these results demonstrate two critical regulators of LPA signaling and open up new avenues to further our understanding of atherothrombosis.

Lysophosphatidic acid (LPA) is a bioactive lipid with a plethora of biological functions, including roles in cell survival, proliferation, and migration. Although high-performance liquid chromatography electrospray ionization tandem mass spectrometry (HPLC ESI-MS/MS) technology has been used to measure the levels of LPA in human blood, serum and plasma, current methods cannot readily detect the minute levels of LPA from cell culture. In this study, a novel HPLC ESI-MS/MS method with enhanced sensitivity was developed which allows accurate measurements of LPA levels with a limit of quantitation at approximately 10 femtomoles. The method was validated by quantitation of LPA levels in the media of previously characterized cell lines ectopically expressing autotaxin. Autotaxin overexpression induced an increase in several subspecies of LPA while others remained unchanged. Lastly, this HPLC ESI-MS/MS method was validated via biological assays previously utilized to assay LPA production. Hence, this new HPLC ESI-MS/MS will allow researchers to measure in vitro LPA levels and also distinguish between specific LPA subspecies for the delineation of individual biological mechanisms.

The simplest phospholipid, lysophosphatidic acid (LPA), is a heat stable component of serum known for its proliferative and migratory activities in cancer cells. Strong evidence suggests that LPA production and expression of its receptors are dysregulated in multiple human malignancies. The mechanism behind LPA-mediated tumor cell growth and oncogenesis remains poorly understood. In this thesis project I used ovarian and other cancer cells as a model system to examine the hypothesis that LPA present in the tumor microenvironment is a pathophysiological determinant of hyperactive de novo lipogenesis and aerobic glycolysis, two hallmarks of cancer cells. We demonstrated that LPA induced proteolytic activation of sterol regulatory element binding proteins (SREBPs) in a cancer specific manner, leading to activation of the SREBP-FAS (fatty acid synthase) lipogenic pathway. Treatment of cancer cell lines with LPA also led to dephosphorylation and inhibition of AMP-activated kinase (AMPK), thereby activating acetyl CoA carboxylase (ACC). Moreover, these effects of LPA were mediated by LPA2, a receptor subtype overexpressed in multiple cancers, providing an explanation for the cancer specific regulation of FAS and ACC by LPA. Downstream of the LPA2 receptor, we identified the Gα12-Rho-Rock pathway to activate SREBPs and the Gαq-PLC (phospholipase C) pathway to inactivate AMPK. Consistent with LPA mediated activation of the key lipogenic enzymes FAS and ACC, LPA stimulated de novo lipid synthesis via LPA2, leading to accumulation of intracellular triacylglycerol and phospholipids. Pharmacological and molecular inhibition of LPA2, FAS or ACC attenuated LPA-dependent cell proliferation, indicating that upregulation of lipid synthesis is an integral component of the proliferative response to LPA. In further support of this, downregulation of LPA2 expression led to dramatic inhibition of anchorage-dependent and –independent growth of ovarian cancer cells. To support increased biomass generation, rapidly proliferating cancer cells enhance carbon influx by activating glycolysis. In the next part of the study, we investigated if LPA signaling was also involved in activating aerobic glycolysis in cancer cells. LPA indeed activated glycolysis in ovarian and other cancer cells but failed to elicit this response in non-transformed cells, suggesting a cancer specific role of LPA in regulation of glucose metabolism. While LPA had no effect on glucose uptake, we found that LPA altered expression of multiple genes involved in glucose metabolism. The most significant observation was that LPA treatment dramatically upregulated expression of HK-2, one of the rate-limiting glycolytic enzymes. We explored the underlying mechanism and found that LPA activates HK-2 transcription through LPA2-mediated activation of SREBP-1. Two sterol regulator elements (SREs) on the human HK-2 promoter were identified to be responsible for LPA activation of the promoter. DNA pulldown and chromatin immunoprecipitation assays confirmed that SREBP-1 bound to these SREs in LPA-treated cells. Although in ovarian cancer cells, LPA treatment also stabilized Hif-1α protein, an established activator of HK-2 and glycolysis, LPA-regulated HK-2 expression and glycolysis was largely independent of Hif-1α. These results established that LPA stimulates glycolysis via the LPA2-SREBP-HK-2 cascade in neoplastic cells. Taken together, this dissertation provides the first evidence for regulation of cancer cell metabolism by LPA. The results indicate that LPA signaling is causally linked to lipogenic and glycolytic phenotypes of cancer cells. Therefore, targeting the key LPA2 receptor could offer a novel and innovative approach to blocking tumor-specific metabolism.

Lysophosphatidic acid (LPA) is a potent bioactive phospholipid mediator that functions through multiple G protein couple receptors (GPCRs). LPA is elevated in ascites of ovarian cancer patients and is involved in growth, survival and metastasis of ovarian cancer cells. Gene promoter analyses revealed that some LPA-target genes share similar sets of binding sites for prominent transcription factors posing the possibility of a general mechanism for activation of their expression by LPA. Detailed investigation of the mechanisms of regulation of cyclooxygenase 2 (Cox-2), a paradigm of LPA-regulated genes, showed that LPA robustly upregulated the expression of Cox-2 in ovarian cancer cells through multiple receptors. LPA induced rapid increase in Cox-2 mRNA and significantly enhanced the stability of Cox-2 transcript with the support of mRNA binding protein HuR. The effects of LPA on Cox-2 transcriptional activation include essential involvement of transcription factor, C/EBP-b. Further studies on mechanisms of activation of C/EBP-b demonstrated that LPA increased phosphorylation, binding and transcriptional activities of C/EBP-b. In addition, activation of C/EBP-b and LPA-target genes required contribution from EGFR. This novel crosstalk between LPA GPCRs and EGFR in mediating transcription factors activation was further explored by investigating the mechanisms of activation of AP-1 and NF-kB by LPA. Activation of AP-1 family of proteins by LPA relied heavily on basal inputs from EGFR as inhibition of EGFR kinase activity with AG1478 caused significant loss of LPA-induced AP-1 expression, binding and transcription activities. Although HGF and other agonists of RTK only weakly stimulate LPA-target genes and transcription factors in ovarian cancer cells, costimulation with HGF in the presence of AG1478 restored LPA signals to both C/EBP-b and AP-1. This suggests an obligatory role for a RTK in LPA-induced transcriptional activation, not necessarily inputs from EGFR. Interestingly, inhibition of EGFR with AG1478 did not interfere with LPA-induced NF-kB activation. Pharmacological inhibition and molecular targeting revealed that only a subset of G proteins participate in the crosstalk between LPA receptors and EGFR. Collectively, these results demonstrate the presence of at least two signals downstream of LPA receptors: one dependent on basal RTK activity and another mediated directly by LPA GPCRs.

The role of endogenous molecules in facilitating stem cell differentiation into cardiomyocytes is yet to be fully understood. SPC and S1P, common biolipids, promote cardiac differentiation of mesenchymal stem cells and cardiac progenitor cells, however, the same potential of closely related lysophosphatidic acid (LPA) has only recently become evident. The initial cardio-protection offered by elevated LPA levels in response to acute myocardial infarction and the ability of this biolipid to mediate other cellular fates served as a rationale to investigate the ability of LPA to mediate the cardiac differentiation of the murine P19 teratocarcinoma cell line and further examine the role of signalling molecules critical to lineage commitment. All experiments were carried out using P19 stem cells, cultured in supplemented alpha-minimal essential medium. Cells were aggregated into embryoid bodies in the presence of 5µM LPA in non-tissue grade Petri dishes over the course of 4 days to commence the differentiation process. Inhibitors were added 60 minutes before LPA while control cells were cultured in medium only. Embryoid bodies were transferred to 6-well tissue culture grade plates and cultured for a further 6 days. Cardiac differentiation was assessed by examining the expression of ventricular myosin light chain (MLC1v) by western blot and the role of LPA receptors 1-4, PKC, PI3K, MAPKs, and NF-κB were determined by examining the changes in this expression in the presence of selective inhibitors. The induction and regulation of GATA4, MEF2C, ATF-2, JNK, and YAP was also determined by western blotting. The activity and regulation of transcription factors, AP-1 and NF-κB, and the MAPKs was determined using ELISA kits. LPA induced the differentiation of P19 cells into cardiomyocytes most effectively when used at a concentration of 5µM as evidenced by the expression of MLC1v on day 10 of the differentiation process. Inhibition of LPA receptor 4 (0.1mg/mL Suramin), LPA receptors 1/3 (20µM Ki16425), LPA receptor 2 (7.5nM H2L5186303), PKC (10µM BIM-1), PI3K (20µM LY294002), ERK (20µM PD98059), JNK (10µM SP600125), and NF-κB (0.01nM CAY10470) blocked LPA induced expression of MLC1v. GATA4, MEF2C, pcJun, pJunD, and pATF2 expression increased in a time-dependent manner peaking at day 10 in LPA treated cells. GATA4 and pcJun expression was suppressed by all the inhibitors whereas MEF2C expression was unaffected by CAY10470, pJunD expression was unaffected by H2L5186303, pATF2 and NF-κB expression was unaffected by LY294002, but the latter was enhanced by Suramin. JNK was transiently phosphorylated in all cells whereas YAP was dephosphorylated 24-48 hours after EB formation in LPA treated cells and were both affected by Ki16425 and partially by H2L5186303 treatment. In conclusion, the studies carried out in this thesis have shown that LPA mediates the cardiac differentiation of P19 cells through LPA receptor 2, partially through receptors 1/3, and possibly through receptor 4. Conceivably downstream of these receptors, PKC, PI3K, MAPK, and NF-κB signalling pathways converge on the regulation of cardiac-specific transcription factors GATA4 and MEF2C along with ubiquitous transcription factor AP-1. JNK signalling is initiated through LPA receptors 1/3 and partially through receptor 2 to commence the cardiac program however the role of JNK and YAP in the proliferation of aggregating EBs is yet to be entirely established.

Signaling lipids such as diacylglycerol (DAG) and the phosphatidylinositol polyphosphates (PIPns) play crucial roles in numerous cellular pathways. However, characterization of their activities is hindered by the complexity of associated signaling pathways and of the membrane environment. To address this issue, we have developed lipid probes that are effective for characterizing biological events using different applications, including activity-based probing (PIPns and DAG) and microarray analysis (PIPns). The activity-based probes have been applied to label receptor targets in multiple cancer cell proteomes through photocrosslinking followed by click reactions. The probes were found to label several proteins, as judged by on-gel fluorescence, and labeling was abrogated through various controls, such as heat denaturation and competition. Proteomic studies have been successfully performed to identify protein targets through biotin enrichment followed by mass spectrometric analysis. For microarray analysis, functionalized PIPn probes were synthesized and applied to develop a high throughput microarray analysis to measure protein-lipid binding affinity. These approaches will be invaluable for characterizing PIPn/DAG-regulated events and their involvement in disease. The design, synthesis and application of these lipid probes are included in this dissertation. In addition, the design and synthesis of other lipid probes are discussed, such as bis(monoacylglycero)phosphate (BMP), and lysophophatidylcholine (LPC) analogs.